Full Press Release Details
PLYMOUTH MEETING, Pa.,March 9, 2026/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:
Eurogin HPV Conference (Vienna, Austria)
Date:Thursday, March 19Time:8:00 AM CETPresentation:DNA Immunotherapy INO-3107 Demonstrates Long-Term Surgical Intervention Reduction in HPV-6 & 11 RRP
World Vaccine Congress DC (Washington, DC)
Date:Monday, March 30Time:11:50 AM ETPresentation:Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVID
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visitwww.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567,[email protected]Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505,[email protected]
SOURCE INOVIO Pharmaceuticals, Inc.